Skip to main content
ICCC
NASDAQ Life Sciences

ImmuCell Q2 Net Income Soars 266% on $2M Settlement and Strong Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.9
Mkt Cap
$98.61M
52W Low
$4.52
52W High
$12.1
52W Position info
141% above low
Off High info
9.9% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ICCC has more than doubled off its 52-week low of $4.52.

Summary

ImmuCell reported Q2 net income of $1.83 million ($0.20 EPS), up 266% year-over-year, boosted by a $2 million legal settlement and 11.5% sales growth. The 10-Q also revealed a USDA approval to extend colostrum expiration limits and plans for an $8 million manufacturing expansion.


Key Events · Earnings and Guidance · ICCC

  • Q2 Net Income Up 266%

    Net income reached $1.83 million ($0.20 per diluted share) versus $0.50 million ($0.06) in Q2 2025, driven by an 11.5% increase in product sales to $7.19 million and a $2.0 million settlement gain.

  • $2M Settlement Boosts Results

    The company recorded a $2.0 million settlement from Norbrook Laboratories as other operating income, resolving claims for operating costs related to the Re-Tain product development.

  • USDA Approval to Release Reserve

    On July 31, 2026, the USDA approved an extension of expiration limits for colostrum, allowing ImmuCell to release a $233,665 inventory reserve to cost of goods sold in Q3 2026.

  • Manufacturing Expansion Underway

    The Board authorized a two-phase expansion: Phase One ($3.5 million, ~12 months) adds freeze-drying capacity; Phase Two ($4.5 million, ~6 months) expands colostrum processing capacity.


Analysis · ICCC · Life Sciences

A one-time $2.0 million settlement from a former contract manufacturer and an 11.5% revenue increase drove ImmuCell's second quarter net income to $1.83 million, up from $0.50 million a year earlier. The company also disclosed a USDA approval that will release a $233,665 inventory reserve next quarter, and detailed a two-phase manufacturing expansion costing up to $8 million to meet growing demand for its First Defense product line.

At the time of this filing, ICCC was trading at $10.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.6M. The 52-week trading range was $4.52 to $12.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ICCC - Latest Insights

ICCC
Aug 13, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.90
Real-time Price: $10.55 info
Change: -$0.350 (-3%) info
Market Cap: $98.61M info
ICCC
Jul 09, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.46
Real-time Price: $10.55 info
Change: -$0.905 (-8%) info
Market Cap: $98.61M info
ICCC
Jun 17, 2026, 2:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.49
Real-time Price: $10.55 info
Change: +$1.06 (+11%) info
Market Cap: $98.61M info
ICCC
Jun 10, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.67
Real-time Price: $10.55 info
Change: +$0.880 (+9%) info
Market Cap: $98.61M info
ICCC
Jun 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.67
Real-time Price: $10.55 info
Change: +$0.880 (+9%) info
Market Cap: $98.61M info